NCT03469934View on ClinicalTrials.gov

Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 14, 2017

Primary Completion Date

October 30, 2018

Study Completion Date

October 30, 2018

Conditions
Eosinophilic Asthma
Interventions
BIOLOGICAL

Etokimab

Administered on Day 1 over 1 hour by IV infusion

DRUG

Placebo

Administered on Day 1 over 1 hour by IV infusion

Trial Locations (7)

48375

Pulmonary & Critical Care Specialists, Novi

61761

Midwest Allergy Sinus Asthma, Normal

73034

OK Clinical Research, LLC, Edmond

97504

Allergy & Asthma Center of Southern Oregon, Medford

M239Q

Medicines Evaluation Unit, Manchester

LE3 9QP

Glenfield Hospital, Leicester

OX3 7LE

Churchill Hospital, Oxford

Sponsors

Lead Sponsor

AnaptysBio, Inc.
All Listed Sponsors
lead

AnaptysBio, Inc.

INDUSTRY

NCT03469934 - Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma | Biotech Hunter | Biotech Hunter